196 related articles for article (PubMed ID: 15603511)
1. The tumor suppressor gene TP53: implications for cancer management and therapy.
Seemann S; Maurici D; Olivier M; Caron de Fromentel C; Hainaut P
Crit Rev Clin Lab Sci; 2004; 41(5-6):551-83. PubMed ID: 15603511
[TBL] [Abstract][Full Text] [Related]
2. p53 as a target for anti-cancer drug development.
Bouchet BP; Caron de Fromentel C; Puisieux A; Galmarini CM
Crit Rev Oncol Hematol; 2006 Jun; 58(3):190-207. PubMed ID: 16690321
[TBL] [Abstract][Full Text] [Related]
3. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
4. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53.
Russo D; Ottaggio L; Foggetti G; Masini M; Masiello P; Fronza G; Menichini P
Biochim Biophys Acta; 2013 Aug; 1833(8):1904-13. PubMed ID: 23545415
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
9. Effect of a two-base insertion mutation of the
Asada H; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
Am J Vet Res; 2019 Jul; 80(7):680-688. PubMed ID: 31246118
[TBL] [Abstract][Full Text] [Related]
10. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.
Xia Y; Li X; Sun W
Curr Gene Ther; 2020; 20(2):127-141. PubMed ID: 32951572
[TBL] [Abstract][Full Text] [Related]
11. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
12. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
13. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.
McCormick F
Semin Cancer Biol; 2000 Dec; 10(6):453-9. PubMed ID: 11170867
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in p53 research: an interdisciplinary perspective.
Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effects of nitroreductase mutants and p53.
Razmkhah M; Habibagahi M; Alizadeh F; Hosseini A; Ghaderi A; Searle PF; Jaberipour M
J Cancer Res Ther; 2014; 10(3):665-70. PubMed ID: 25313757
[TBL] [Abstract][Full Text] [Related]
16. Small molecule activators of the p53 response.
Ladds MJGW; Laín S
J Mol Cell Biol; 2019 Mar; 11(3):245-254. PubMed ID: 30689917
[TBL] [Abstract][Full Text] [Related]
17. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.
Guillot C; Falette N; Paperin MP; Courtois S; Gentil-Perret A; Treilleux I; Ozturk M; Puisieux A
Oncogene; 1997 Jan; 14(1):45-52. PubMed ID: 9010231
[TBL] [Abstract][Full Text] [Related]
18. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
Blandino G; Valenti F; Sacconi A; Di Agostino S
Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
[TBL] [Abstract][Full Text] [Related]
19. Translating p53 into the clinic.
Cheok CF; Verma CS; Baselga J; Lane DP
Nat Rev Clin Oncol; 2011 Jan; 8(1):25-37. PubMed ID: 20975744
[TBL] [Abstract][Full Text] [Related]
20. Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
Donehower LA
Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
